OncoMatch/Clinical Trials/NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Is NCT06203210 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Topotecan for small cell lung cancer.
Treatment: Ifinatamab deruxtecan · Topotecan · Amrubicin · Lurbinectedin — This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Metastatic disease required
extensive-stage small cell lung cancer (ES-SCLC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — systemic therapy for SCLC
Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval [CTFI] (duration from stop date of the platinum agent in 1L therapy to radiological PD) of ≥30 days.
Cannot have received: B7-H3 targeted agent (orlotamab, enoblituzumab, ifinatamab deruxtecan)
Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.
Cannot have received: antibody drug conjugate with exatecan derivative (trastuzumab deruxtecan)
Exception: if not discontinued due to treatment-related toxicities
Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
Cannot have received: topoisomerase I inhibitor
Has received any of the comparators used in this study or any topoisomerase I inhibitor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group · Springdale, Arkansas
- Clinical Research Providence Medical Foundation · Fullerton, California
- UCLA Hematology-Oncology · Los Angeles, California
- UCSF Mission Bay Mission Hall · San Francisco, California
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06203210 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted agent, antibody drug conjugate with exatecan derivative, topoisomerase I inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages